• Connor Langworth-Green, Saisha Patel, Zane Jaunmuktane, Edwin Jabbari, Huw Morris, Maria Thom, Andrew Lees, John Hardy, Michael Zandi, and Karen Duff.
• University College London Medical School, University College London, London, UK.
• Lancet Neurol. 2023 May 1; 22 (5): 430442430-442.

AbstractTauopathies are a heterogeneous group of neurodegenerative disorders that are characterised by the aggregation of the microtubule-associated protein tau into filamentous inclusions within neurons and glia. Alzheimer's disease is the most prevalent tauopathy. Despite years of intense research efforts, developing disease-modifying interventions for these disorders has been very challenging. The detrimental role that chronic inflammation plays in the pathogenesis of Alzheimer's disease is increasingly recognised; however, it is largely ascribed to the accumulation of amyloid β, leaving the effect of chronic inflammation on tau pathology and neurofibrillary tangle-related pathways greatly overlooked. Tau pathology can independently arise secondary to a range of triggers that are each associated with inflammatory processes, including infection, repetitive mild traumatic brain injury, seizure activity, and autoimmune disease. A greater understanding of the chronic effects of inflammation on the development and progression of tauopathies could help forge a path for the establishment of effective immunomodulatory disease-modifying interventions for clinical use.Copyright © 2023 Elsevier Ltd. All rights reserved.

12 keywords...

hide…